%	O
%	O
TITLE	O

Evaluation	O
of	O
a	O
combined	O
triple	O
method	O
to	O
detect	O
causative	O
HPV	O
in	O
oral	O
and	O
oropharyngeal	O
squamous	O
cell	O
carcinomas	O
:	O
p16	B-HPV_Lab_Technique
Immunohistochemistry	I-HPV_Lab_Technique
,	O
Consensus	B-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
HPV	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
DNA	I-HPV_Lab_Technique
,	O
and	O
In	B-HPV_Lab_Technique
Situ	I-HPV_Lab_Technique
Hybridization	I-HPV_Lab_Technique
.	O

%	O
%	O
ABSTRACT	O

Recent	O
emerging	O
evidences	O
identify	O
Human	O
Papillomavirus	O
(	O
HPV	O
)	O
related	O
Head	O
and	O
Neck	O
squamous	O
cell	O
carcinomas	O
(	O
HN	O
-	O
SCCs	O
)	O
as	O
a	O
separate	O
subgroup	O
among	O
Head	O
and	O
Neck	O
Cancers	O
with	O
different	O
epidemiology	O
,	O
histopathological	O
characteristics	O
,	O
therapeutic	O
response	O
to	O
chemo	O
-	O
radiation	O
treatment	O
and	O
clinical	O
outcome	O
.	O

However	O
,	O
there	O
is	O
not	O
a	O
worldwide	O
consensus	O
on	O
the	O
methods	O
to	O
be	O
used	O
in	O
clinical	O
practice	O
.	O

The	O
endpoint	O
of	O
this	O
study	O
was	O
to	O
demonstrate	O
the	O
reliability	O
of	O
a	O
triple	O
method	O
which	O
combines	O
evaluation	O
of	O
:	O
1	O
.	O

p16	O
protein	O
expression	O
by	O
immunohistochemistry	O
(	O
p16	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
IHC	I-HPV_Lab_Technique
)	I-HPV_Lab_Technique
;	O
2	O
.	O

HPV	O
-	O
DNA	O
genotyping	O
by	O
consensus	B-HPV_Lab_Technique
HPV	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
DNA	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
methods	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
Consensus	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
)	O
;	O
and	O
3	O
viral	O
integration	O
into	O
the	O
host	O
by	O
in	B-HPV_Lab_Technique
situ	I-HPV_Lab_Technique
hybridization	I-HPV_Lab_Technique
method	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
ISH	I-HPV_Lab_Technique
)	I-HPV_Lab_Technique
.	O

This	O
triple	O
method	O
has	O
been	O
applied	O
to	O
HN	O
-	O
SCC	O
originated	O
from	O
oral	O
cavity	O
(	O
OSCC	O
)	O
and	O
oropharynx	O
(	O
OPSCC	O
)	O
,	O
the	O
two	O
anatomical	O
sites	O
in	O
which	O
high	O
risk	O
(	O
HR	O
)	O
HPVs	O
have	O
been	O
clearly	O
implicated	O
as	O
etiologic	O
factors	O
.	O

Methylation	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
Specific	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
MSP	I-HPV_Lab_Technique
)	O
was	O
performed	O
to	O
study	O
inactivation	O
of	O
p16	O
-	O
CDKN2a	O
locus	O
by	O
epigenetic	O
events	O
.	O

Reliability	O
of	O
multiple	O
methods	O
was	O
measured	O
by	O
Kappa	O
statistics	O
.	O
All	O
the	O
HN	O
-	O
SCCs	O
confirmed	O
HPV	O
positive	O
by	O
PCR	B-HPV_Lab_Technique
and	O
/	O
or	O
ISH	B-HPV_Lab_Technique
were	O
also	O
p16	B-HPV_Lab_Technique
positive	I-HPV_Lab_Technique
by	I-HPV_Lab_Technique
IHC	I-HPV_Lab_Technique
,	O
with	O
the	O
latter	O
showing	O
a	O
very	O
high	O
level	O
of	O
sensitivity	O
as	O
single	O
test	O
(	O
100	O
%	O
in	O
both	O
OSCC	O
and	O
OPSCC	O
)	O
but	O
lower	O
specificity	O
level	O
(	O
74	O
%	O
in	O
OSCC	O
and	O
93	O
%	O
in	O
OPSCC	O
)	O
.	O
Concordance	O
analysis	O
between	O
ISH	B-HPV_Lab_Technique
and	O
Consensus	O
PCR	B-HPV_Lab_Technique
showed	O
a	O
faint	O
agreement	O
in	O
OPSCC	O
(	O
Îº	O
=	O
0	O
.	O
38	O
)	O
and	O
a	O
moderate	O
agreement	O
in	O
OSCC	O
(	O
Îº	O
=	O
0	O
.	O
44	O
)	O
.	O

Furthermore	O
,	O
the	O
addition	O
of	O
double	O
positive	O
score	O
(	O
ISHpositive	O
and	O
Consensus	O
PCR	O
positive	O
)	O
increased	O
significantly	O
the	O
specificity	O
of	O
HR	O
-	O
HPV	O
detection	O
on	O
formalin	O
-	O
fixed	O
paraffin	O
embedded	O
(	O
FFPE	O
)	O
samples	B-HPV_Sample_Type
(	O
100	O
%	O
in	O
OSCC	O
and	O
78	O
.	O
5	O
%	O
in	O
OPSCC	O
)	O
,	O
but	O
reduced	O
the	O
sensitivity	O
(	O
33	O
%	O
in	O
OSCC	O
and	O
60	O
%	O
in	O
OPSCC	O
)	O
.	O

The	O
significant	O
reduction	O
of	O
sensitivity	O
by	O
the	O
double	O
method	O
was	O
compensated	O
by	O
a	O
very	O
high	O
sensitivity	O
of	O
p16	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
IHC	I-HPV_Lab_Technique
detection	O
in	O
the	O
triple	O
approach	O
.	O

Although	O
HR	O
-	O
HPVs	O
detection	O
is	O
of	O
utmost	O
importance	O
in	O
clinical	O
settings	O
for	O
the	O
Head	O
and	O
Neck	O
Cancer	O
patients	O
,	O
there	O
is	O
no	O
consensus	O
on	O
which	O
to	O
consider	O
the	O
'	O
golden	O
standard	O
'	O
among	O
the	O
numerous	O
detection	O
methods	O
available	O
either	O
as	O
single	O
test	O
or	O
combinations	O
.	O

Until	O
recently	O
,	O
quantitative	O
E6	O
RNA	O
PCR	B-HPV_Lab_Technique
has	O
been	O
considered	O
the	O
'	O
golden	O
standard	O
'	O
since	O
it	O
was	O
demonstrated	O
to	O
have	O
very	O
high	O
accuracy	O
level	O
and	O
very	O
high	O
statistical	O
significance	O
associated	O
with	O
prognostic	O
parameters	O
.	O

In	O
contrast	O
,	O
quantitative	O
E6	O
DNA	O
PCR	B-HPV_Lab_Technique
has	O
proven	O
to	O
have	O
very	O
high	O
level	O
of	O
accuracy	O
but	O
lesser	O
prognostic	O
association	O
with	O
clinical	O
outcome	O
than	O
the	O
HPV	O
E6	O
oncoprotein	O
RNA	O
PCR	B-HPV_Lab_Technique
.	O

However	O
,	O
although	O
it	O
is	O
theoretically	O
possible	O
to	O
perform	O
quantitative	O
PCR	B-HPV_Lab_Technique
detection	O
methods	O
also	O
on	O
FFPE	O
samples	B-HPV_Sample_Type
,	O
they	O
reach	O
the	O
maximum	O
of	O
accuracy	O
on	O
fresh	O
frozen	O
tissue	B-HPV_Sample_Type
.	I-HPV_Sample_Type

Furthermore	O
,	O
worldwide	O
diagnostic	O
laboratories	O
have	O
not	O
all	O
the	O
same	O
ability	O
to	O
analyze	O
simultaneously	O
both	O
FFPE	O
and	O
fresh	O
tissues	B-HPV_Sample_Type
with	O
these	O
quantitative	O
molecular	O
detection	O
methods	O
.	O

Therefore	O
,	O
in	O
the	O
current	O
clinical	O
practice	O
a	O
p16	O
-	O
IHC	O
test	O
is	O
considered	O
as	O
sufficient	O
for	O
HPV	O
diagnostic	O
in	O
accordance	O
with	O
the	O
recently	O
published	O
Head	O
and	O
Neck	O
Cancer	O
international	O
guidelines	O
.	O

Although	O
p16	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
IHC	I-HPV_Lab_Technique
may	O
serve	O
as	O
a	O
good	O
prognostic	O
indicator	O
,	O
our	O
study	O
clearly	O
demonstrated	O
that	O
it	O
is	O
not	O
satisfactory	O
when	O
used	O
exclusively	O
as	O
the	O
only	O
HPV	O
detecting	O
method	O
.	O

Adding	O
ISH	B-HPV_Lab_Technique
,	O
although	O
known	O
as	O
less	O
sensitive	O
than	O
PCR	B-HPV_Lab_Technique
-	O
based	O
detection	O
methods	O
,	O
has	O
the	O
advantage	O
to	O
preserve	O
the	O
morphological	O
context	O
of	O
HPV	O
-	O
DNA	O
signals	O
in	O
FFPE	O
samples	B-HPV_Sample_Type
and	O
,	O
thus	O
increase	O
the	O
overall	O
specificity	O
of	O
p16	O
/	O
Consensus	O
PCR	B-HPV_Lab_Technique
combination	O
tests	O
.	O

%	O
%	O
METHODS	O

Population	O
and	O
study	O
design	O

The	O
study	O
group	O
was	O
composed	O
of	O
33	B-Study_Cohort
patients	I-Study_Cohort
with	I-Study_Cohort
SCC	I-Study_Cohort
of	O
the	O
oral	O
cavity	O
(	O
n	O
=	O
11	O
cases	O
with	O
OSCC	O
)	O
or	O
of	O
the	O
oropharynx	O
(	O
n	O
=	O
22	O
cases	O
with	O
OPSCC	O
)	O
(	O
see	O
Table	O
To	O
further	O
increase	O
the	O
number	O
of	O
cases	O
,	O
a	O
Tissue	B-HPV_Sample_Type
Microar	O
-	O
ray	O
(	O
TMA	O
)	O
composed	O
of	O
53	B-Study_Cohort
OSCC	I-Study_Cohort
cases	I-Study_Cohort
from	O
National	O
Cancer	O
Institute	O
of	O
Napoli	O
,	O
Italy	B-Study_Location
,	O
has	O
employed	O
.	O

The	O
study	O
included	O
also	O
15	O
negative	O
control	O
cases	O
of	O
normal	O
oral	O
(	O
n	O
=	O
5	O
)	O
,	O
pharyngeal	O
(	O
n	O
=	O
5	O
)	O
and	O
laryngeal	O
(	O
n	O
=	O
5	O
)	O
mucosa	O
;	O
3	O
control	O
cases	O
of	O
cervical	O
HR	O
-	O
HPV	O
positive	O
lesions	O
(	O
n	O
=	O
2	O
cases	O
of	O
HSIL	O
and	O
n	O
=	O
1	O
case	O
of	O
invasive	O
cervical	O
carcinoma	O
)	O
,	O
and	O
1	O
positive	O
LR	O
-	O
HPV	O
positive	O
control	O
case	O
of	O
Juvenile	O
Onset	O
Recurrent	O
Respiratory	O
Papillomatosis	O
(	O
JO	O
-	O
RRP	O
)	O
,	O
all	O
of	O
them	O
previously	O

characterised	O
for	O
HPV	O
by	O
PCR	B-HPV_Lab_Technique
followed	O
by	O
direct	O
sequencing	O
.	O

Informed	O
consent	O
was	O
obtained	O
from	O
all	O
participants	O
or	O
from	O
their	O
relatives	O
.	O

The	O
histopathologi	O
-	O
cal	O
diagnosis	O
of	O
OSCC	O
/	O
OPSCC	O
was	O
made	O
at	O
the	O
Section	O
of	O
Anatomic	O
Pathology	O
of	O
the	O
University	O
of	O
Foggia	O
-	O
Foggia	O
,	O
Italy	O
.	O

Microscopic	O
evaluation	O
was	O
performed	O
by	O
two	O
oral	O
pathologists	O
(	O
GP	O
and	O
PB	O
)	O
determining	O
the	O
degree	O
of	O
differentiation	O
according	O
to	O
WHO	O
grading	O
sys	O
-	O
tem	O
,	O
and	O
establishing	O
tumor	O
extent	O
according	O
to	O
the	O
TNM	O
system	O
.	O

The	O
collection	O
of	O
representative	O
cases	O
of	O
OSCCs	O
and	O
OPSCCs	O
has	O
been	O
made	O
available	O
for	O
this	O
study	O
through	O
the	O
active	O
collaboration	O
between	O
multiple	O
Italian	O
Universities	O
and	O
Cancer	O
Research	O
Centres	O
(	O
Uni	O
-	O
versity	O
of	O
Foggia	O
,	O
University	O
of	O
Napoli	O
Federico	O
II	O
,	O
Napoli	O
National	O
Cancer	O
Institute	O
,	O
University	O
of	O
Palermo	O
,	O
University	O
of	O
Ancona	O
)	O
.	O

Consecutive	O
cases	O
have	O
been	O
ran	O
-	O
domly	O
chosen	O
from	O
cohorts	O
known	O
for	O
their	O
HPV	O
preva	O
-	O
lence	O
as	O
previously	O
published	O
[	O
,	O
3	O
]	O
and	O
were	O
analyzed	O
for	O
HPV	O
-	O
DNA	O
using	O
FFPE	O
specimens	B-HPV_Sample_Type
obtained	O
from	O
surgery	O
with	O
curative	O
intention	O
;	O
in	O
addition	O
some	O
cases	O
have	O
been	O
also	O
analysed	O
using	O
cytological	O
brushing	O
materials	O
in	O
preoperative	O
setting	O
.	O

In	B-HPV_Lab_Technique
situ	I-HPV_Lab_Technique
hybridization	I-HPV_Lab_Technique
was	O
performed	O
using	O
commercially	O
available	O
panels	O
of	O
LR	O
-	O
HPV	O
and	O
HR	O
-	O
HPV	O
probe	O
and	O
automated	O
chromo	O
-	O
genic	O
ISH	B-HPV_Lab_Technique
detection	O
for	O
HPV	O
-	O
DNA	O
on	O
serial	O
sections	O
FFPE	O
blocks	O
.	O

On	O
consecutive	O
serial	O
section	O
from	O
FFPE	O
p16	B-HPV_Lab_Technique
immunohistochemistry	I-HPV_Lab_Technique
was	O
performed	O
using	O
p16	O
monoclonal	O
Ab	O
and	O
standard	O
LSAB	O
-	O
HRP	O
technique	O
.	O

Methylation	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
Specific	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
MSP	I-HPV_Lab_Technique
)	I-HPV_Lab_Technique
on	O
consecutive	O
serial	O
20	O
micron	O
sections	O
was	O
performed	O
to	O
study	O
inactivation	O
of	O
p16CDKN2a	O
locus	O
.	O

Immunohistochemistry	O
to	O
detect	O
p16	O
expression	O
(	O
p16	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
IHC	I-HPV_Lab_Technique
)	O

Four	O
μm	O
serial	O
sections	O
from	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
blocks	O
were	O
cut	O
and	O
mounted	O
on	O
poly	O
-	O
L	O
-	O
lysine	O
coated	O
glass	O
slides	O
.	O

Immunostaining	O
was	O
performed	O
by	O
linked	O
streptavidin	O
-	O
biotin	O
horseradish	O
peroxidase	O
techni	O
-	O
que	O
(	O
LSAB	O
-	O
HRP	O
)	O
.	O

After	O
sequential	O
deparaffinization	O
and	O
rehydration	O
,	O
the	O
slides	O
were	O
treated	O
with	O
0	O
.	O
3	O
%	O
H2O2	O
for	O
15	O
min	O
to	O
quench	O
endogenous	O
peroxidase	O
.	O

Antigen	O
retrieval	O
was	O
performed	O
by	O
microwave	O
heating	O
-	O
a	O
1st	O
time	O
for	O
3	O
min	O
at	O
650	O
W	O
,	O
a	O
2nd	O
and	O
a	O
3rd	O
time	O
at	O
350	O
W	O
-	O
of	O
the	O
slides	O
immersed	O
in	O
10	O
mM	O
citrate	O
buffer	O
pH	O
6	O
.	O

After	O
microwaving	O
,	O
the	O
sections	O
were	O
blocked	O
for	O
60	O
min	O
with	O
1	O
.	O
5	O
%	O
normal	O
horse	O
serum	O
(	O
Santa	O
Cruz	O
Biotechnol	O
-	O
ogy	O
,	O
Santa	O
Cruz	O
,	O
CA	O
)	O
diluted	O
in	O
PBS	O
buffer	O
before	O
the	O
reaction	O
with	O
primary	O
antibody	O
(	O
Ab	O
)	O
.	O

Primary	O
monoclo	O
-	O
nal	O
anti	O
-	O
p16	O
antibody	O
(	O
BD	O
-	O
Pharmingen	O
;	O
clone	O
G175	O
-	O
405	O
)	O
was	O
diluted	O
1	O
:	O
150	O
with	O
0	O
.	O
05	O
M	O
Tris	O
-	O
HCl	O
buffer	O
pH	O
7	O
.	O
4	O
containing	O
1	O
%	O
bovine	O
serum	O
albumin	O
and	O
incubated	O
overnight	O
.	O

After	O
two	O
washes	O
with	O
PBS	O
,	O
the	O
slides	O
were	O
treated	O
with	O
biotinylated	O
species	O
-	O
specific	O
secondary	O
anti	O
-	O
bodies	O
and	O
streptavidin	O
-	O
biotin	O
enzyme	O
reagent	O
(	O
DAKO	O
,	O

Glostrup	O
,	O
Denmark	O
)	O
,	O
and	O
the	O
color	O
developed	O
by	O
3	O
,	O
3’	O
-	O
diaminobenzidine	O
tetrahydrochloride	O
chromogen	O
solu	O
-	O
tion	O
(	O
DAB	O
)	O
.	O

Sections	O
were	O
counterstained	O
with	O
Mayer’s	O
haematoxylin	O
and	O
mounted	O
using	O
xylene	O
-	O
based	O
mounting	O
medium	O
.	O

Negative	O
control	O
slides	O
without	O
primary	O
anti	O
-	O
body	O
were	O
included	O
for	O
each	O
staining	O
.	O

The	O
results	O
of	O
the	O
immunohistochemical	O
staining	O
were	O
evaluated	O
separately	O
by	O
two	O
investigators	O
.	O

Stained	O
cells	O
were	O
counted	O
in	O
at	O
least	O
10	O
high	O
powered	O
(	O
40×	O
)	O
fields	O
using	O
an	O
Olympus	O
BX41	O
microscope	O
.	O

For	O
each	O
case	O
,	O
the	O
cumulative	O
percen	O
-	O
tage	O
of	O
positive	O
cells	O
among	O
all	O
sections	O
examined	O
was	O
determined	O
.	O

Tissue	B-HPV_Sample_Type
microarray	O
based	O
immunohistochemistry	O

For	O
tissue	B-HPV_Sample_Type
microarray	O
construction	O
,	O
areas	O
of	O
interest	O
rich	O
in	O
non	O
-	O
necrotic	O
tumor	O
cells	O
,	O
were	O
identified	O
on	O
corre	O
-	O
sponding	O
haematoxylin	O
and	O
eosin	O
-	O
stained	O
sections	O
and	O
marked	O
on	O
the	O
source	O
paraffin	O
block	O
.	O

The	O
source	O
block	O
was	O
cored	O
and	O
a	O
0	O
.	O
6	O
mm	O
core	O
transferred	O
to	O
the	O
recipient	O
master	O
block	O
using	O
Galileo	O
TMA	O
CK	O
3500	O
Tissue	O
Micro	O
-	O
arrayer	O
;	O
ISE	O
TMA	O
Software	O
(	O
Integrated	O
System	O
Engineer	O
-	O
ing	O
,	O
Milan	O
,	O
Italy	O
)	O
.	O

Two	O
cores	O
from	O
different	O
areas	O
(	O
one	O
representative	O
of	O
superficial	O
and	O
one	O
deep	O
invasion	O
)	O
and	O
whenever	O
possible	O
one	O
core	O
of	O
normal	O
mucosa	O
of	O
the	O
same	O
tissue	B-HPV_Sample_Type
block	O
were	O
arrayed	O
for	O
each	O
case	O
.	O

All	O
the	O
donor	O
cores	O
were	O
formatted	O
into	O
one	O
recipient	O
block	O
.	O

H	O
&	O
E	O
staining	O
of	O
a	O
4	O
-	O
μm	O
TMA	O
section	O
was	O
used	O
to	O
verify	O
all	O
samples	B-HPV_Sample_Type
.	O

Immunohistochemical	O
analysis	O
on	O
4	O
-	O
μm	O
TMA	O
serial	O
sections	O
was	O
performed	O
by	O
using	O
Ventana	O
Benchmark®	O
autostainer	O
and	O
/	O
or	O
manual	O
standard	O
linked	O
streptavidin	O
-	O
biotin	O
horseradish	O
peroxidase	O
technique	O
(	O
LSAB	O
-	O
HRP	O
)	O
,	O
according	O
to	O
the	O
best	O
protocol	O
for	O
each	O
antibody	O
tested	O
in	O
our	O
laboratory	O
.	O

PCR	B-HPV_Lab_Technique
analysis	O

HPV	O
-	O
DNA	O
was	O
detected	O
using	O
nested	B-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
(	O
MY	O
/	O
GP	O
pri	O
-	O
mers	O
)	O
,	O
and	O
HPV	O
genotype	O
was	O
determined	O
by	O
direct	O
sequencing	O
of	O
PCR	B-HPV_Lab_Technique
fragments	O
.	O

Three	O
types	O
of	O
control	O
were	O
included	O
in	O
each	O
reaction	O
series	O
:	O
blank	O
control	O
,	O
HPV	O
negative	O
Wi	O
cells	O
as	O
negative	O
control	O
and	O
HPV	O
-	O
18	O
DNA	O
-	O
positive	O
HeLa	O
cells	O
,	O
in	O
dilutions	O
from	O
20	O
,	O
000	O
-	O
50	O
,	O
000	O
down	O
to	O
2	O
-	O
5	O
HPV	O
-	O
DNA	O
copies	O
,	O
as	O
positive	O
control	O
.	O

HPV	O
-	O
DNA	O
was	O
amplified	O
by	O
PCR	B-HPV_Lab_Technique
assay	O
using	O
primers	O
useful	O
for	O
samples	B-HPV_Sample_Type
with	O
a	O
low	O
copy	O
number	O
of	O
HPV	O
(	O
MY09	O
-	O
MY11	O
primer	O
pair	O
in	O
combination	O
with	O
GP5	O
-	O
GP6	O
primer	O
pair	O
)	O
as	O
previously	O
demonstrated	O
[	O
]	O
and	O
amplifications	O
were	O
performed	O
in	O
a	O
Mastercycler	O
gradient	O
thermal	O
cycler	O
(	O
Eppendorf	O
,	O
Hamburg	O
,	O
Germany	O
)	O
;	O
amplification	O
products	O
were	O
analyzed	O
in	O
8	O
%	O
polyacrylamide	O
gel	O
.	O

Sequencing	O
analysis	O

HPV	O
genotyping	O
was	O
based	O
on	O
direct	O
sequencing	O
of	O
MY	B-HPV_Lab_Technique
or	I-HPV_Lab_Technique
MY	I-HPV_Lab_Technique
/	I-HPV_Lab_Technique
GP	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
fragments	O
.	O

Amplification	O
products	O
were	O
purified	O
by	O
Microcon	O
YM	O
-	O
100	O
(	O
Amicon	O
-	O
Millipore	O
,	O

Billerica	O
,	O
MA	O
)	O
;	O
the	O
sequence	O
of	O
both	O
DNA	O
strands	O
was	O
determined	O
by	O
the	O
BigDye	O
Ready	O
Reaction	O
Kit	O
in	O
the	O
automatic	O
sequencer	O
ABI	O
Prism	O
310	O
Analyzer	O
(	O
both	O
from	O
Perkin	O
-	O
Elmer	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
.	O

Alignments	O
were	O
obtained	O
from	O
the	O
GenBank	O
on	O
-	O
line	O
BLAST	O
server	O
and	O
HPV	O
sequences	O
downloaded	O
from	O
the	O
HPV	O
database	O

In	B-HPV_Lab_Technique
situ	I-HPV_Lab_Technique
hybridization	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
ISH	I-HPV_Lab_Technique
)	O
for	O
HPV	O
-	O
DNA	O
detection	O
in	O
morphological	O
context	O

ISH	B-HPV_Lab_Technique
signal	O
patterns	O
has	O
been	O
reported	O
to	O
be	O
associated	O
to	O
the	O
status	O
of	O
HPV	O
showing	O
the	O
test	O
the	O
power	O
to	O
detect	O
episomal	O
,	O
integrated	O
,	O
or	O
mixed	O
forms	O
]	O
.	O

Recently	O
,	O
a	O
commercially	O
available	O
probe	O
set	O
for	O
HR	O
-	O
HPV	O
has	O
showed	O
an	O
agreement	O
with	O
Consensus	O
PCR	B-HPV_Lab_Technique
of	O
85	O
%	O
in	O
FFPE	O
tissue	B-HPV_Sample_Type
specimens	I-HPV_Sample_Type
from	O
patients	O
with	O
cervical	O
intrae	O
-	O
pithelial	O
neoplasia	O
and	O
cervical	O
carcinoma	O
[	O
45	O
]	O
.	O

This	O
A	O
commercially	O
available	O
HPV	B-HPV_Lab_Technique
ISH	I-HPV_Lab_Technique
system	I-HPV_Lab_Technique
has	I-HPV_Lab_Technique
been	I-HPV_Lab_Technique
used	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
Ventana	I-HPV_Lab_Technique
Inform	I-HPV_Lab_Technique
HPV	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
Tucson	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
AZ	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
USA	I-HPV_Lab_Technique
)	O
to	O
detect	O
inte	O
-	O
gration	O
or	O
episomic	O
status	O
in	O
our	O
study	O
.	O

Briefly	O
,	O
in	B-HPV_Lab_Technique
situ	I-HPV_Lab_Technique
hybridization	I-HPV_Lab_Technique
was	O
performed	O
using	O
the	O
Benchmark®	O
plate	O
and	O
an	O
alkaline	O
-	O
phosphatase	O
coupled	O
antibody	O
detection	O
method	O
.	O

The	O
hybridization	O
signals	O
were	O
shown	O
with	O
Tet	O
-	O
razole	O
Blu	O
and	O
Fast	O
Red	O
nuclear	O
counterstaining	O
.	O

The	O
commercially	O
available	O
Ventana	O
kit	O
includes	O
the	O
following	O
probes	O
for	O
HR	O
-	O
HPVs	O
16	O
,	O
18	O
,	O
31	O
,	O
33	O
,	O
35	O
,	O
39	O
,	O
45	O
,	O
51	O
,	O
52	O
,	O
56	O
,	O

58	O
,	O
e	O
66	O
(	O
Iiform	O
HPV	O
family	O
-	O
III	O
16	O
Probe	O
;	O
Ventana	O
-	O
Roche	O
)	O
;	O
and	O
the	O
following	O
probes	O
for	O
LR	O
-	O
HPVs	O
,	O
6	O
,	O
11	O
(	O
Inform	O
HPV	O
famly	O
-	O
II	O
6	O
Probe	O
;	O
Ventana	O
-	O
Roche	O
)	O
.	O

ISH	B-HPV_Lab_Technique
evaluation	O

ISH	B-HPV_Lab_Technique
signals	O
were	O
determined	O
for	O
at	O
least	O
10	O
high	O
pow	O
-	O
ered	O
fields	O
as	O
described	O
above	O
.	O

OSCC	O
/	O
OPSCC	O
cases	O
showing	O
prominent	O
nuclear	O
punctuated	O
(	O
discreet	O
dot	O
-	O
like	O
)	O
signals	O
have	O
been	O
considered	O
as	O
integrative	O
(	O
I	O
)	O
.	O

Cases	O
with	O
exclusive	O
nuclear	O
cluster	O
signals	O
as	O
been	O
eval	O
-	O
uated	O
as	O
episomal	O
(	O
E	O
)	O
.	O

The	O
episomal	O
pattern	O
appeared	O
as	O
large	O
,	O
homogeneous	O
,	O
globular	O
navy	O
-	O
blue	O
precipitate	O
within	O
the	O
cell	O
nucleus	O
.	O

Recently	O
it	O
has	O
been	O
suggested	O
that	O
the	O
signals	O
originating	O
from	O
integrated	O
virus	O
can	O
be	O
hidden	O
in	O
a	O
background	O
of	O
episomal	O
HPV	O
;	O
therefore	O
cases	O
showing	O
a	O
prevalent	B-Incidence_or_Prevalence
nuclear	O
cluster	O
signals	O
along	O
with	O
also	O
focal	O
punctuated	O
signals	O
of	O
integration	O
have	O
been	O
evaluated	O
as	O
mixed	O
episomic	O
-	O
integrative	O
(	O
E	O
-	O
I	O
)	O
.	O

According	O
to	O
the	O
manufacturer	O
,	O
artifacts	O
or	O
non	O
-	O
specific	O
staining	O
is	O
regarded	O
as	O
:	O
non	O
-	O
cellular	O
stromal	O
precipitates	O
;	O
cytoplasms	O
of	O
PMNs	O
(	O
polymorphonucleated	O
cells	O
)	O
,	O
eosi	O
-	O
nophils	O
,	O
lymphocytes	O
and	O
endothelial	O
cells	O
;	O
and	O
staining	O
of	O
nucleoli	O

Methylation	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
specific	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
MSP	I-HPV_Lab_Technique
)	I-HPV_Lab_Technique
to	O
analyze	O
promoter	O
methylation	O
of	O
CDKN2a	O
/	O
INK4a	O
locus	O

Following	O
careful	O
examination	O
of	O
Haematoxylin	O
-	O
eosin	O
stained	O
slides	O
,	O
we	O
selected	O
tissue	B-HPV_Sample_Type
sections	O
with	O
the	O

greatest	O
proportion	O
of	O
malignant	O
tissue	B-HPV_Sample_Type
.	O

Paraffin	O
blocks	O
with	O
corresponding	O
normal	O
epithelium	O
distant	O
from	O
tumor	O
were	O
as	O
selected	O
.	O

Five	O
10	O
μM	O
sections	O
were	O
cut	O
from	O
each	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tumor	O
sam	B-HPV_Sample_Type
-	I-HPV_Sample_Type
ple	I-HPV_Sample_Type
and	O
transferred	O
into	O
micro	O
centrifuge	O
tubes	O
.	O

The	O
par	O
-	O
affin	O
was	O
dissolved	O
using	O
xylene	O
followed	O
by	O
two	O
washes	O
with	O
100	O
%	O
ethanol	O
and	O
one	O
wash	O
with	O
phosphate	O
-	O
buf	O
-	O
fered	O
saline	O
.	O

The	O
samples	B-HPV_Sample_Type
were	O
then	O
incubated	O
in	O
lysis	O
solution	O
(	O
proteinase	O
K	O
-	O
Qiagen	O
,	O
20	O
mg	O
/	O
ml	O
,	O
50	O
micro	O
-	O
L	O
;	O
1	O
M	O
Tris	O
HCl	O
solution	O
,	O
10	O
micro	O
-	O
L	O
;	O
0	O
,	O
5	O
M	O
EDTA	O
,	O
2	O
micro	O
-	O
L	O
;	O
10	O
%	O
SDS	O
100	O
micro	O
-	O
L	O
;	O
distilled	O
water	O
838	O
ml	O
)	O
over	O
-	O
night	O
at	O
55°C	O
.	O

Reversal	O
of	O
cross	O
-	O
linking	O
was	O
performed	O
by	O
adding	O
NaCl	O
(	O
final	O
concentration	O
0	O
.	O
7	O
M	O
)	O
and	O
incubating	O
at	O
65°C	O
for	O
4	O
h	O
.	O

DNA	O
was	O
recovered	O
using	O
the	O
Wizard	O
DNA	O
clean	O
-	O
up	O
kit	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
)	O
according	O
to	O
the	O
manufacturer’s	O
protocols	O
.	O

To	O
test	O
the	O
integrity	O
of	O
iso	O
-	O
lated	O
DNA	O
the	O
housekeeping	O
haemoglobin	O
gene	O
was	O
amplified	O
by	O
PCR	B-HPV_Lab_Technique
and	O
visualized	O
by	O
gel	O
electrophoresis	O
for	O
both	O
control	O
and	O
pathological	O
samples	B-HPV_Sample_Type
.	O

The	O
haemo	O
-	O
globin	O
gene	O
primers	O
used	O
were	O
:	O
forward	O
,	O
5’	O
-	O
GAA	O
GAG	O
CCA	O
AGG	O
ACA	O
GGT	O
A	O
-	O
3’	O
,	O
and	O
reverse	O
,	O
5’	O
-	O
GGA	O
AAA	O

TAG	O
ACC	O
AAT	O
AGG	O
CAG	O
3’	O
.	O

The	O
DNA	O
quantity	O
was	O
evaluated	O
by	O
a	O
NanoDrop	O
Spectrophotometer	O
(	O
CELBIO	O
)	O
.	O

Sodium	O
bisulfate	O
modification	O
of	O
100	O
μg	O
DNA	O
for	O
each	O
sample	B-HPV_Sample_Type
was	O
performed	O
using	O
the	O
EZ	O
DNA	O
Methylation	O
Kit	O
(	O
Zymo	O
Research	O
,	O
Orange	O
,	O
CA	O
)	O
following	O
the	O
manufac	O
-	O
turer’s	O
protocol	O
,	O
with	O
the	O
addition	O
of	O
a	O
5	O
min	O
initial	O
incu	O
-	O
bation	O
at	O
95°C	O
prior	O
to	O
addition	O
of	O
the	O
denaturation	O
reagent	O
.	O

The	O
steps	O
to	O
reverse	O
cross	O
-	O
linking	O
in	O
the	O
extrac	O
-	O
tion	O
procedure	O
as	O
well	O
as	O
the	O
95°C	O
incubation	O
ensure	O
more	O
complete	O
melting	O
of	O
the	O
DNA	O
and	O
thus	O
more	O
com	O
-	O
plete	O
sodium	O
bisulfite	O
conversion	O
of	O
these	O
formalin	O
-	O
fixed	O
specimens	B-HPV_Sample_Type
.	O

All	O
Methylation	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
Specific	I-HPV_Lab_Technique
PCRs	I-HPV_Lab_Technique
were	O
opti	O
-	O
mized	O
to	O
detect	O
>	O
5	O
%	O
methylated	O
substrate	O
in	O
each	O
sam	B-HPV_Sample_Type
-	I-HPV_Sample_Type
ple	I-HPV_Sample_Type
.	O

Each	O
experiment	O
was	O
performed	O
in	O
triplicate	O
.	O

Methylated	O
and	O
unmethylated	O
DNA	O
were	O
equally	O
recov	O
-	O
ered	O
from	O
fixed	O
material	O
and	O
only	O
non	O
-	O
degraded	O
DNA	O
samples	B-HPV_Sample_Type
were	O
selected	O
.	O

The	O
primers	O
used	O
for	O
Nested	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
to	O
flank	O
methylated	O
/	O
unmethylated	O
(	O
M	O
/	O
U	O
)	O
CDKN2a	O
/	O
INK4a	O
locus	O
have	O
been	O
reported	O
in	O
Table	O

Statistical	O
analysis	O

The	O
data	O
were	O
analyzed	O
by	O
the	O
Stanton	O
Glantz	O
statistical	O
software	O
3	O
(	O
MS	O
-	O
DOS	O
)	O
and	O
GraphPad	O
Prism	O
software	O

Table	O
3	O
Primers	O
used	O
to	O
detect	O
methylated	O
and	O
unmethylated	O
p16	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
CDKN2a	I-HPV_Lab_Technique
locus	I-HPV_Lab_Technique
by	I-HPV_Lab_Technique
Nested	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
MSP	I-HPV_Lab_Technique
)	O

P16	O
EF	O
AGAAAGAGGAGGGGTTGGTTGG	O

P16	O
ER	O
ACRCCCRCACCTCCTCTACC	O

P16	O
IMR	O
GACCCCGAACCGCGACCGTAA	O

P16	O
IMF	O
TTATTAGAGGGTGGGGCGGATCGC	O

P16	O
IUR	O
CAACCCCAAACCACAACCATAA	O

P16	O
IUF	O
TTATTAGAGGGTGGGGTGGATTGT	O

version	O
4	O
.	O
00	O
for	O
Windows	O
(	O
Graph	O
Pad	O
software	O
San	O
Diego	O
,	O
CA	O
,	O

Reliability	O

The	O
HPV	O
‘positivity’	O
as	O
evaluated	O
by	O
different	O
methods	O
was	O
assessed	O
using	O
Kappa	O
statistics	O
.	O

The	O
reliability	O
of	O
ISH	B-HPV_Lab_Technique
and	O
Consensus	B-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
was	O
determined	O
using	O
Fleiss’	O
intra	O
-	O
class	O
correlation	O
coefficient	O
(	O
ICCC	O
)	O
]	O
.	O

The	O
Kappa	O
coefficients	O
were	O
divided	O
into	O
categories	O
as	O
described	O
by	O
Landis	O
and	O
Kock	O

Abbreviations	O

HPV	O
:	O
Human	O
papilloma	O
virus	O
;	O
HN	O
-	O
SCC	O
:	O
Head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
;	O
IHC	O
:	O
Immunohistochemistry	O
;	O
DNA	O
:	O
Desoxyribonucleic	O
acid	O
;	O
PCR	O
:	O
Polymerase	O
chain	O
reaction	O
;	O
ISH	O
:	O
In	O
situ	O
hybridization	O
;	O
OSCC	O
:	O
Oral	O
squamous	O
cell	O
carcinoma	O
;	O
OPSCC	O
:	O
Oro	O
-	O
pharyngeal	O
squamous	O
cell	O
carcinoma	O
;	O
MSP	O
:	O
Methylation	O
-	O
specific	O
PCR	O
;	O
FFPE	O
:	O
Formalin	O
fixed	O
paraffin	O
embedded	O
;	O
RNA	O
:	O
Ribonucleic	O
acid	O
;	O
USA	O
:	O
United	O
States	O
of	O
America	O
;	O
Rb	O
:	O
Retinoblastoma	O
protein	O
;	O
LOH	O
:	O
Loss	O
of	O
heterozygosity	O
;	O
WHO	O
:	O
World	O
Health	O
Organization	O
;	O
EBV	O
:	O
Epstein	O
barr	O

virus	O
;	O
TMA	O
:	O
Tissue	O
micro	O
-	O
array	O
;	O
LR	O
-	O
HPV	O
:	O
Low	O
risk	O
human	O
papilloma	O
virus	O
;	O
HR	O
-	O
HPV	O
:	O
High	O
risk	O
human	O
papilloma	O
virus	O
;	O
I	O
:	O
Integrative	O
pattern	O
;	O
E	O
-	O
I	O
:	O
Episomal	O
-	O
integrative	O
pattern	O
;	O
E	O
:	O
Episomal	O
pattern	O
;	O
ORF	O
:	O
open	O
reading	O
frame	O
;	O
TCs	O
:	O
tonsillar	O
cancers	O
;	O
QPCR	O
:	O
Quantitative	O
polymerase	O
chain	O
reaction	O
;	O
JO	O
-	O
RRP	O
:	O
Juvenile	O
onset	O
recurrent	O
respiratory	O
papillomatosis	O
;	O
LSAB	O
-	O
HRP	O
:	O
Linked	O
streptavidin	O
-	O
biotin	O
horseradish	O
peroxidase	O
technique	O
;	O
DAB	O
:	O
3	O
,	O
3’	O
-	O
diaminobenzidine	O
tetrahydrochloride	O
chromogen	O
solution	O
;	O
HPF	O
:	O
High	O
power	O

field	O
analyzed	O
;	O
ICCC	O
:	O
Intra	O
-	O
class	O
correlation	O
coefficient	O
.	O

